[HEP DART 2017] HBSAG在10年慢性乙型肝炎病毒患者中的血清学变化

StephenW

SEROCLEARANCE OF HBSAG IN CHRONIC HEPATITIS B VIRUS PATIENTS ON A 10 YEARS EXPERIENCE.
Felipe Pereira de Souza, Mariana Akemi
Nabeshima, Luís Cláudio Alfaia Mendes, Denise Cerqueira Paranaguá-Vezozzo, Rodrigo Martins Abreu, Flair
José Carrilho, Suzane Kioko Ono
Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology
University of São Paulo School of Medicine, São Paulo, Brazil;
HEP DART 2017
ABSTRACT NUMBER: 13
December 6 th 2017

BACKGROUND
In Brazil, HBV antivirals are given by government (SUS – Unique/Universal Health System). Universal access to every citizen who needs treatment
HBsAg
loss, with or without anti-HBs seroconversion, is an optimal endpoint, as it indicates profound suppression of HBV replication and viral protein expression
Long term HBsAg seroclearence frequency with nucleos(t)ide analogs (NUC) treatment is still not well established in Brazil

CONCLUSIONS
□Long term viral suppression with nucleoside analogues leads to HBsAg
loss and cure may be well within reach with oral antivirals.
□When resistance to lamivudine is not present HBsAg loss is possible

StephenW

[HEP DART 2017] HBSAG在10年慢性乙型肝炎病毒患者中的血清学变化。
Felipe Pereira de Souza，Mariana Akemi
Nabeshima，LuísCláudioAlfaia Mendes，Denise CerqueiraParanaguá-Vezozzo，Rodrigo Martins Abreu，Flair
JoséCarrilho，Suzane Kioko Ono
临床胃肠病学和肝病学系，消化内科
巴西圣保罗圣保罗医学院;
HEP DART 2017
摘要编号：13
2017年12月6日

背景
在巴西，HBV抗病毒药物由政府提供（SUS - Unique / Universal Health System）。普遍接触每个需要治疗的公民
HBsAg
有或没有抗-HBs血清转化的损失是最佳的终点，因为它表明HBV复制和病毒蛋白表达的显着抑制
长期HBsAg血清学检查频率与核苷（酸）类似物（NUC）治疗在巴西仍未建立

结论
□核苷类似物的长期病毒抑制导致HBsAg
口服抗病毒药物可能会很好的治愈。
□当对拉米夫定没有抗药性时，可能会出现HBsAg消失

StephenW

请阅读完整的摘要
http://regist2.virology-educatio ... /HEPDART/63_Ono.pdf

antiHBVren

不错！赞！绝对的正能量